Compounds that modulate intracellular calcium

A method of alleviating, abating, or ameliorating the symptoms of rheumatoid arthritis, asthma, psoriasis, arthritis, ulcerative colitis, rejection of skin transplant, or renal transplantation in a mammal comprising administering to the mammal a compound or pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof having the structure of Formula (VIA):

• wherein:
• R′1 is
• L2 is —NH—C(═O)—, or —C(═O)NH—;
• X is CR3 or N;
• Y is independently selected from CR9 or N;
• R2 is C1-C6alkyl, C3-C8cycloalkyl, C1-C6haloalkyl, C2-C8heterocycloalkyl, C1-C4alkyleneC2-C8heterocycloalkyl, aryl, heteroaryl, fused aryl or fused heteroaryl;
• wherein C1-C6alkyl, C3-C8cycloalkyl, C1-C6haloalkyl, C2-C8heterocycloalkyl, C1-C4alkyleneC2-C8heterocycloalkyl, aryl, heteroaryl, fused aryl or fused heteroaryl is optionally substituted with at least one R3;
• R3 is independently selected from H, F, D, Cl, Br, I, —CN, —NO2, —OH, —CF3, —OCF3, —OR5, C1-C6alkyl, C3-C8cycloalkyl, C1-C6heteroalkyl, C1-C6haloalkyl, C2-C8heterocycloalkyl, optionally substituted aryl, optionally substituted O-aryl, optionally substituted heteroaryl,
• n is an integer selected from 0-2;
• R9 is independently selected from halogen, C1-C6alkyl, C1-C6haloalkyl, —OR5, —OCF3, C1-C6 carbonylalkyl, or —CF3;
• or two R9 attached to the same carbon atom form an oxetane ring;
• R10 is selected from halogen, C1-C6alkyl, C1-C6haloalkyl, —OR5, —OCF3, C1-C6 carbonylalkyl, or —CF3;
• and
• R5 is independently selected from H, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, phenyl, and benzyl.